BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 145,861 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 145,861 shares of the firm’s stock in a transaction that occurred on Tuesday, July 14th. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95. Following the transaction, the chief executive officer directly owned 8,122 shares of the company’s stock, valued at approximately $2,484,925.90. This trade represents a 94.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Trading Up 0.9%

NASDAQ:ONC opened at $306.56 on Wednesday. The company’s 50 day moving average price is $290.24 and its 200-day moving average price is $308.90. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $253.95 and a 52 week high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The stock has a market cap of $33.64 billion, a price-to-earnings ratio of 68.58 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion during the quarter. On average, equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ONC shares. Royal Bank Of Canada lifted their price target on shares of BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Barclays lowered their price objective on shares of BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating on the stock in a research report on Tuesday. Wolfe Research initiated coverage on shares of BeOne Medicines in a report on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price on the stock. Guggenheim lifted their target price on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $395.00 target price on shares of BeOne Medicines in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, BeOne Medicines has a consensus rating of “Moderate Buy” and an average target price of $390.92.

Institutional Trading of BeOne Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of ONC. Cetera Investment Advisers purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at about $455,000. Rhumbline Advisers bought a new stake in BeOne Medicines during the 2nd quarter worth approximately $275,000. Arrowstreet Capital Limited Partnership bought a new stake in BeOne Medicines during the 2nd quarter worth approximately $505,000. Invesco Ltd. purchased a new position in BeOne Medicines during the second quarter valued at approximately $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines during the second quarter valued at approximately $68,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.